Bavarian Nordic $123 million rights issue to get pivotal Prostvac trial started
This article was originally published in Scrip
Executive Summary
Bavarian Nordic of Denmark is hoping to raise DKK650 million ($123 million) through a rights issue to fund development of its prostate cancer vaccine Prostvac.